{"license":"https://creativecommons.org/licenses/by/4.0/","dataset":"events","count":3,"eventFilters":{"event":null,"eventMatched":null,"events":["evt-pbm-insulin-complaint-2024","evt-pbm-express-scripts-settlement-2026","evt-pbm-caremark-settlement-2026"],"eventsMatched":true,"matchedEventCount":3,"matchedEventIds":["evt-pbm-insulin-complaint-2024","evt-pbm-express-scripts-settlement-2026","evt-pbm-caremark-settlement-2026"],"unmatchedEvents":[],"stage":null,"stageMatched":null,"type":null,"typeMatched":null,"agency":null,"proceeding":"pbm-insulin-rebate-case","proceedingMatched":true,"proceedingId":"proceeding-pbm-insulin","proceedingSlug":"pbm-insulin-rebate-case"},"rows":[{"id":"evt-pbm-insulin-complaint-2024","eventDate":"2024-09-20","year":2024,"title":"FTC files administrative complaint against the three largest PBMs","agency":"Federal Trade Commission","eventType":"complaint","stage":"litigation","summary":"The FTC brought an administrative action alleging anticompetitive and unfair rebating and formulary practices involving Caremark, Express Scripts, OptumRx, and affiliated GPOs.","significance":"Adds alleged conduct and patient-harm context to the PBM profile. The allegations remain distinct from the descriptive concentration evidence and do not supply missing individual shares.","relatedMarketIds":["mkt-pbm"],"sourceId":"ftc-pbm-insulin-complaint-2024","docketNumber":"Docket No. 9437","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management","shortName":"PBMs"}],"sourceTitle":"FTC Sues Prescription Drug Middlemen for Artificially Inflating Insulin Drug Prices","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2024/09/ftc-sues-prescription-drug-middlemen-artificially-inflating-insulin-drug-prices","sourceProfileHref":"/sources/ftc-pbm-insulin-complaint-2024","recordProfileHref":"/enforcement/records/pbm-insulin-complaint-2024","proceedingId":"proceeding-pbm-insulin","proceedingSlug":"pbm-insulin-rebate-case","proceedingTitle":"FTC insulin-rebate administrative matter","proceedingType":"administrative_case","proceedingSequence":1,"proceedingEventCount":3,"proceedingProfileHref":"/enforcement/proceedings/pbm-insulin-rebate-case","namedEntities":[{"id":"pent-ascent-health","slug":"ascent-health-services-llc","name":"Ascent Health Services, LLC","role":"respondent"},{"id":"pent-caremark-rx","slug":"caremark-rx-llc","name":"Caremark Rx, LLC","role":"respondent"},{"id":"pent-emisar-pharma","slug":"emisar-pharma-services-llc","name":"Emisar Pharma Services LLC","role":"respondent"},{"id":"pent-express-scripts","slug":"express-scripts-inc","name":"Express Scripts, Inc.","role":"respondent"},{"id":"pent-optumrx","slug":"optumrx-inc","name":"OptumRx, Inc.","role":"respondent"},{"id":"pent-zinc-health","slug":"zinc-health-services-llc","name":"Zinc Health Services, LLC","role":"respondent"}]},{"id":"evt-pbm-express-scripts-settlement-2026","eventDate":"2026-02-04","year":2026,"title":"FTC announces proposed consent agreement with Express Scripts","agency":"Federal Trade Commission","eventType":"settlement","stage":"remedy","summary":"The FTC announced a proposed consent agreement with Express Scripts and affiliated entities addressing formulary design, patient cost sharing, manufacturer compensation, plan-sponsor transparency, community-pharmacy reimbursement, and related business practices.","significance":"Records announced remedy terms in the pending administrative matter. The filing does not establish realized savings, changes in PBM market structure, or a basis for calculating the withheld market HHI.","relatedMarketIds":["mkt-pbm"],"sourceId":"ftc-express-scripts-settlement-2026","docketNumber":"Docket No. 9437","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management","shortName":"PBMs"}],"sourceTitle":"FTC Secures Landmark Settlement with Express Scripts to Lower Drug Costs for American Patients","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2026/02/ftc-secures-landmark-settlement-express-scripts-lower-drug-costs-american-patients","sourceProfileHref":"/sources/ftc-express-scripts-settlement-2026","recordProfileHref":"/enforcement/records/pbm-express-scripts-settlement-2026","proceedingId":"proceeding-pbm-insulin","proceedingSlug":"pbm-insulin-rebate-case","proceedingTitle":"FTC insulin-rebate administrative matter","proceedingType":"administrative_case","proceedingSequence":2,"proceedingEventCount":3,"proceedingProfileHref":"/enforcement/proceedings/pbm-insulin-rebate-case","namedEntities":[{"id":"pent-ascent-health","slug":"ascent-health-services-llc","name":"Ascent Health Services, LLC","role":"remedy_subject"},{"id":"pent-express-scripts","slug":"express-scripts-inc","name":"Express Scripts, Inc.","role":"remedy_subject"}]},{"id":"evt-pbm-caremark-settlement-2026","eventDate":"2026-07-14","year":2026,"title":"FTC announces proposed consent agreement with Caremark","agency":"Federal Trade Commission","eventType":"settlement","stage":"remedy","summary":"The FTC announced a proposed consent agreement with Caremark and Zinc Health Services addressing formulary design, point-of-sale rebates, fee structures, plan-sponsor transparency, community-pharmacy reimbursement, and access to pharmacy hub services.","significance":"Records announced remedy terms in the pending administrative matter. The filing does not establish realized savings, changes in PBM market structure, or a basis for calculating the withheld market HHI.","relatedMarketIds":["mkt-pbm"],"sourceId":"ftc-caremark-settlement-2026","docketNumber":"Docket No. 9437","markets":[{"id":"mkt-pbm","slug":"us-pharmacy-benefit-management","name":"U.S. pharmacy benefit management","shortName":"PBMs"}],"sourceTitle":"FTC Secures Major Settlement with Caremark Resolving Antitrust Case Against Second Drug Middleman","sourcePublisher":"Federal Trade Commission","sourceUrl":"https://www.ftc.gov/news-events/news/press-releases/2026/07/ftc-secures-major-settlement-caremark-resolving-antitrust-case-against-second-drug-middleman","sourceProfileHref":"/sources/ftc-caremark-settlement-2026","recordProfileHref":"/enforcement/records/pbm-caremark-settlement-2026","proceedingId":"proceeding-pbm-insulin","proceedingSlug":"pbm-insulin-rebate-case","proceedingTitle":"FTC insulin-rebate administrative matter","proceedingType":"administrative_case","proceedingSequence":3,"proceedingEventCount":3,"proceedingProfileHref":"/enforcement/proceedings/pbm-insulin-rebate-case","namedEntities":[{"id":"pent-caremark-rx","slug":"caremark-rx-llc","name":"Caremark Rx, LLC","role":"remedy_subject"},{"id":"pent-zinc-health","slug":"zinc-health-services-llc","name":"Zinc Health Services, LLC","role":"remedy_subject"}]}]}